London, United Kingdom - August 14, 2026 - Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated clinical-stage global radiotherapeutics company, today announced its participation in ESMO Congress 2026, taking place in Madrid, Spain from October 23 to 27, 2026, and the 39th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Vienna, Austria from October 17 to 21, 2026. The Company will present data from its PSMA-targeted alpha radioconjugate [225Ac]Ac-FL-020 at ESMO and from its c-MET-targeted theranostic RDC program FL-261 at EANM, where Full-Life will also host Booth 420 in Hall X-4.

"Presenting data from both [225Ac]Ac-FL-020 and FL-261 at ESMO and EANM reflects the breadth and progress of our radiotherapeutics pipeline," said Debora Barton, MD, Chief Medical Officer of Full-Life Technologies. "We look forward to engaging with the oncology and nuclear medicine communities as we continue advancing differentiated radiopharmaceutical therapies for patients."

Details of these activities are provided in the table below:

About [225Ac]Ac-FL-020

[225Ac]Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate ("RDC") that entered global Phase 1 clinical studies in 2024. Its targeting vector, FL-020, was discovered using Full-Life's proprietary UniRDC(TM) platform, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic clearance. The U.S. FDA has granted [225Ac]Ac-FL-020 Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer.

About FL-261

FL-261 is Full-Life's potential first-in-class c-MET-targeted theranostic RDC program for multiple solid tumor indications. The program is designed to combine molecular imaging and targeted radiotherapy through a c-MET-binding ligand, supporting the identification and treatment of c-MET-positive tumors. FL-261 emerged from Full-Life's proprietary UniRDC(TM) discovery platform.

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a privately held, fully integrated clinical-stage global radiotherapeutics company with operations worldwide. The Company's mission is to bring the power of radiotherapy to cancer patients globally through an integrated model spanning radiopharmaceutical research and development, production and commercialization. By combining advanced manufacturing capabilities, biological insights and clinical efficiency, Full-Life works to address fundamental challenges in radiopharmaceuticals through pioneering research focused on future cancer treatments. The Company is led by fast-moving entrepreneurs and seasoned scientists with strong life sciences experience and a patient-centered focus.

Media Contacts:

Full-Life

Email: pr@t-full.com

Website: www.full-life.com